NO167576C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider.

Info

Publication number
NO167576C
NO167576C NO875209A NO875209A NO167576C NO 167576 C NO167576 C NO 167576C NO 875209 A NO875209 A NO 875209A NO 875209 A NO875209 A NO 875209A NO 167576 C NO167576 C NO 167576C
Authority
NO
Norway
Prior art keywords
preparation
substituted pyrimidine
pyrimidine nucleosides
therapeutic active
analogy procedure
Prior art date
Application number
NO875209A
Other languages
English (en)
Norwegian (no)
Other versions
NO875209D0 (no
NO167576B (no
NO875209L (no
Inventor
Saad George Rahim
Dorothy Jane Martin Purifoy
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NO875209D0 publication Critical patent/NO875209D0/no
Publication of NO875209L publication Critical patent/NO875209L/no
Publication of NO167576B publication Critical patent/NO167576B/no
Publication of NO167576C publication Critical patent/NO167576C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Silicon Polymers (AREA)
NO875209A 1986-12-15 1987-12-14 Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider. NO167576C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868629892A GB8629892D0 (en) 1986-12-15 1986-12-15 Antiviral compounds

Publications (4)

Publication Number Publication Date
NO875209D0 NO875209D0 (no) 1987-12-14
NO875209L NO875209L (no) 1988-06-16
NO167576B NO167576B (no) 1991-08-12
NO167576C true NO167576C (no) 1991-11-20

Family

ID=10609013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO875209A NO167576C (no) 1986-12-15 1987-12-14 Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider.

Country Status (30)

Country Link
US (1) US5079235A (lt)
EP (3) EP0486477A3 (lt)
JP (2) JPS63165397A (lt)
KR (1) KR880007521A (lt)
CN (2) CN87108265A (lt)
AT (1) ATE88713T1 (lt)
AU (2) AU601529B2 (lt)
CA (1) CA1319143C (lt)
CS (3) CS342591A3 (lt)
DD (2) DD264924A5 (lt)
DE (1) DE3785651T2 (lt)
DK (2) DK654287A (lt)
ES (1) ES2054693T3 (lt)
FI (2) FI875487A (lt)
GB (1) GB8629892D0 (lt)
HU (4) HU199867B (lt)
IE (2) IE930470L (lt)
IL (3) IL84810A (lt)
LT (1) LT2064B (lt)
LV (1) LV5273A3 (lt)
MC (1) MC1882A1 (lt)
MX (1) MX9203216A (lt)
NO (1) NO167576C (lt)
NZ (1) NZ222898A (lt)
PH (2) PH24104A (lt)
PL (3) PL158050B1 (lt)
PT (1) PT86356B (lt)
RU (1) RU2036199C1 (lt)
SU (1) SU1731064A3 (lt)
ZA (1) ZA879382B (lt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2828642B2 (ja) * 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
US5006646A (en) * 1989-02-22 1991-04-09 Yuki Gosei Kogyo Co., Ltd. Process for preparing 2'-deoxy-5-trifluoromethyl-beta-uridine
IE902574A1 (en) * 1989-07-17 1991-02-27 Univ Birmingham Antiviral pyrimidine nucleosides
DD293498A5 (de) * 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9008696D0 (en) * 1990-04-18 1990-06-13 Wellcome Found Anti-viral compounds
GB9012899D0 (en) * 1990-06-09 1990-08-01 Wellcome Found Anti-hbv pyrimidine nucleoside
GB9014618D0 (en) * 1990-06-30 1990-08-22 Wellcome Found Process for the preparation of pyrimidine nucleosides
ATE161722T1 (de) 1990-07-19 1998-01-15 Wellcome Found Enzyminaktivatoren
US5643913A (en) * 1990-07-19 1997-07-01 Glaxo Wellcome Inc. Pharmaceutical compositions of 5-substituted uracil compounds
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations
GB9104165D0 (en) * 1991-02-27 1991-04-17 Wellcome Found Novel entities for hiv therapy
GB9111580D0 (en) * 1991-05-30 1991-07-24 Wellcome Found Nucleoside derivative
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
HU207524B (en) * 1991-11-22 1993-04-28 Mta Koezponti Kemiai Kutato In Industrial process for producing 5-alkyl-2'-deoxy-beta-uridines with stereoselective synthesis
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
JP3739785B2 (ja) * 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
CA2118405A1 (en) * 1992-05-26 1993-09-12 Robert Maurice Ippolito Immunosuppressive and tolerogenic modified lewisc and lacnac compounds
CA2119315A1 (en) * 1993-03-18 1994-09-19 Tsujiaki Hata Nucleoside derivatives and anti-herpes composition
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
CA2241255A1 (en) * 1995-12-22 1997-07-03 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
WO1997027849A1 (fr) * 1996-02-02 1997-08-07 Showa Shell Sekiyu K.K. Medicaments pour traiter les infections provoquees par le virus de l'herpes et compositions preventives pour empecher un retour de l'infection, contenant tous les deux des derives triterpeniques comme principe actif
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7019129B1 (en) 2000-05-09 2006-03-28 Biosearch Technologies, Inc. Dark quenchers for donor-acceptor energy transfer
US7211570B2 (en) * 2001-12-20 2007-05-01 Pharmasset, Inc. Treatment of EBV and KHSV infection
CA2587514A1 (en) 2004-12-03 2006-06-08 Adherex Technologies, Inc. Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
SI2757091T1 (en) 2008-04-01 2018-01-31 Biosearch Technologies, Inc. Stabilized nucleic acid black gas-fluorofor probe
CN101768197A (zh) * 2008-12-29 2010-07-07 北京德众万全药物技术开发有限公司 一种奈拉滨的制备方法
KR20120127709A (ko) 2009-10-14 2012-11-23 애드헤렉스 테크놀로지스 인크. 5－ｆｕ 또는 이의 프로드럭과 ｄｐｄ 억제제의 병용물과 관련된 신경독성의 치료
CA2944155C (en) * 2014-03-30 2023-08-29 Cepheid Modified cytosine polynucleotide oligomers and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601020A (en) * 1978-04-24 1981-10-21 Stichting Grega Vzw 2'-deoxy-5 (2-halogenovinyl)-uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4267171A (en) * 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) * 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
US4274544A (en) * 1980-03-11 1981-06-23 The Continental Group, Inc. Single-piece plastic closure having integral seal forming means
EP0082668A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc 5-(2-Halogenovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in treating viral infections
EP0082667A1 (en) * 1981-12-18 1983-06-29 Beecham Group Plc Pharmaceutical compositions
EP0095294A1 (en) * 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridine compounds, methods for preparing them and their use in medicine
EP0097039A1 (en) * 1982-06-16 1983-12-28 Beecham Group Plc 5-(E-2-halovinyl)-2'-deoxyuridine derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in treating viral infections
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
ATE190064T1 (de) * 1985-09-17 2000-03-15 Wellcome Found Kombination therapeutische nukleoside mit weiteren therapeutisch wirksamen komponenten.
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds

Also Published As

Publication number Publication date
FI941523A0 (fi) 1994-03-31
DE3785651T2 (de) 1993-11-11
IE930471L (en) 1988-06-15
HU199867B (en) 1990-03-28
EP0272065A3 (en) 1988-11-17
NO875209D0 (no) 1987-12-14
EP0272065B1 (en) 1993-04-28
US5079235A (en) 1992-01-07
DD274766A5 (de) 1990-01-03
IL95141A0 (en) 1991-06-10
IL95141A (en) 1992-05-25
MC1882A1 (fr) 1989-01-24
AU626041B2 (en) 1992-07-23
NZ222898A (en) 1990-12-21
ZA879382B (en) 1989-08-30
PL158050B1 (pl) 1992-07-31
DK654287A (da) 1988-06-16
CN1080292A (zh) 1994-01-05
PH24870A (en) 1990-12-26
FI941523A (fi) 1994-03-31
JPH0378370B2 (lt) 1991-12-13
HU202112B (en) 1991-02-28
PL160321B1 (pl) 1993-02-26
PL277927A1 (en) 1989-08-21
LT2064B (lt) 1993-06-15
PH24104A (en) 1990-03-05
DD264924A5 (de) 1989-02-15
JPS63165397A (ja) 1988-07-08
NO167576B (no) 1991-08-12
IL84810A (en) 1992-05-25
ATE88713T1 (de) 1993-05-15
HUT46336A (en) 1988-10-28
JPH03141292A (ja) 1991-06-17
ES2054693T3 (es) 1994-08-16
CS275398B2 (en) 1992-02-19
EP0417560A1 (en) 1991-03-20
IL84810A0 (en) 1988-06-30
EP0486477A3 (en) 1992-06-17
RU2036199C1 (ru) 1995-05-27
CS916187A2 (en) 1991-02-12
DK654287D0 (da) 1987-12-14
AU5989090A (en) 1990-11-08
DK169991A (da) 1991-10-04
IE930470L (en) 1988-06-15
CS342591A3 (en) 1992-04-15
CN87108265A (zh) 1988-07-13
SU1731064A3 (ru) 1992-04-30
PT86356B (pt) 1990-11-07
PL277926A1 (en) 1989-08-21
KR880007521A (ko) 1988-08-27
HU200932B (en) 1990-09-28
CA1319143C (en) 1993-06-15
CS275402B6 (en) 1992-02-19
DK168323B1 (da) 1994-03-14
FI875487A0 (fi) 1987-12-14
FI875487A (fi) 1988-06-16
HU903829D0 (en) 1990-11-28
EP0272065A2 (en) 1988-06-22
GB8629892D0 (en) 1987-01-28
PT86356A (en) 1988-01-01
DK169991D0 (da) 1991-10-04
LV5273A3 (lv) 1993-10-10
DE3785651D1 (de) 1993-06-03
AU601529B2 (en) 1990-09-13
PL160322B1 (pl) 1993-02-26
CS767588A3 (en) 1991-02-12
MX9203216A (es) 1992-07-01
EP0486477A2 (en) 1992-05-20
NO875209L (no) 1988-06-16
PL269462A1 (en) 1989-06-26
HU207735B (en) 1993-05-28
AU8252187A (en) 1988-06-16

Similar Documents

Publication Publication Date Title
NO167576C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituerte pyrimidinnukleosider.
DE3679353D1 (de) Antivirale verbindungen.